Literature DB >> 12627003

Early multiple organ failure after recurrent endotoxemia in the presence of vasoconstrictor-masked hypovolemia.

Frank Hinder1, Henning D Stubbe, Hugo Van Aken, Hideo A Baba, Ulrich R Jahn, Gerhard Brodner, Christian August, Michael Erren, Michael Booke.   

Abstract

OBJECTIVE: Critically ill patients who develop multiple organ failure during systemic inflammatory states are often predisposed to hypovolemia and vasoconstrictor therapy. Although numerous investigations have evaluated the sequelae of systemic inflammation, no data are available on the contribution of chronic vasoconstrictor-masked hypovolemia to organ dysfunction and morphology.
DESIGN: Prospective, randomized laboratory investigation.
SETTING: University research laboratory.
SUBJECTS: Eighteen adult chronically instrumented sheep.
INTERVENTIONS: The animals were randomly assigned to one of three groups. In the norfenefrine-masked hypovolemia plus endotoxemia (NMH+ENDO) group, mean arterial pressures of 80 mm Hg were maintained by using the alpha1-adrenergic catecholamine norfenefrine for 52 hrs during hypovolemia. Hypovolemia was induced by hemorrhage (about 23 mL x kg(-1)) until mean arterial pressures reached 40 mm Hg. Endotoxin (0.5 microg x k(-1)) was then injected after 4, 16, 28, and 40 hrs. The NMH group received norfenefrine-masked hypovolemia but no endotoxin. In the ENDO group, recurrent endotoxemia was induced during normovolemia.
MEASUREMENTS AND MAIN RESULTS: Despite profound differences in fluid management, cardiovascular filling pressures were not statistically different between groups. Endotoxemia induced norfenefrine-refractory shock (p < .05 vs. the other groups) and contributed to renal dysfunction only during vasoconstrictor-masked hypovolemia. Norfenefrine-masked hypovolemia caused disseminated cardiac cell necrosis independent of endotoxemia (p < .05 vs. ENDO).
CONCLUSIONS: Hypovolemia can be masked when volume status is monitored by filling pressures. In this new model of endotoxemia-associated multiple organ failure, chronic vasoconstrictor-masked hypovolemia turned systemic inflammation into a life-threatening condition with renal and cardiovascular failure. Cardiomyocyte necroses were caused by vasoconstrictor-masked hypovolemia but were unrelated to cardiovascular failure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627003     DOI: 10.1097/01.CCM.0000050289.15988.67

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  10 in total

1.  Inhaled nitric oxide for ARDS: searching for a more focused use.

Authors:  Luca M Bigatello; Judith Hellman
Journal:  Intensive Care Med       Date:  2003-10       Impact factor: 17.440

Review 2.  [Volume replacement in intensive care medicine].

Authors:  B Nohé; A Ploppa; V Schmidt; K Unertl
Journal:  Anaesthesist       Date:  2011-05       Impact factor: 1.041

3.  Inhaled nitric oxide reduces lung edema during fluid resuscitation in ovine acute lung injury.

Authors:  Henning D Stubbe; Martin Westphal; Hugo Van Aken; Christoph Hucklenbruch; Stefan Lauer; Uli R Jahn; Frank Hinder
Journal:  Intensive Care Med       Date:  2003-05-24       Impact factor: 17.440

4.  Influence of different volume replacement strategies on inflammation and endothelial activation in the elderly undergoing major abdominal surgery.

Authors:  Joachim Boldt; Michael Ducke; Bernhard Kumle; Michael Papsdorf; Ernst-Ludwig Zurmeyer
Journal:  Intensive Care Med       Date:  2004-01-08       Impact factor: 17.440

5.  Heat shock protein 72 and apoptosis indicate cardiac decompensation during early multiple organ failure in sheep.

Authors:  Hideo A Baba; Jeremias Wohlschlaeger; Henning D Stubbe; Florian Grabellus; Hugo Van Aken; Klaus J Schmitz; Friedrich Otterbach; Kurt W Schmid; Christian August; Bodo Levkau; Frank Hinder
Journal:  Intensive Care Med       Date:  2004-02-24       Impact factor: 17.440

6.  Early versus delayed administration of norepinephrine in patients with septic shock.

Authors:  Xiaowu Bai; Wenkui Yu; Wu Ji; Zhiliang Lin; Shanjun Tan; Kaipeng Duan; Yi Dong; Lin Xu; Ning Li
Journal:  Crit Care       Date:  2014-10-03       Impact factor: 9.097

7.  Evaluation of capillary leakage after vasopressin resuscitation in a hemorrhagic shock model.

Authors:  Roberto Bini; Osvaldo Chiara; Stefania Cimbanassi; Giorgio Olivero; Antonella Trombetta; Paolo Cotogni
Journal:  World J Emerg Surg       Date:  2018-03-05       Impact factor: 5.469

8.  Effects of very early start of norepinephrine in patients with septic shock: a propensity score-based analysis.

Authors:  Gustavo A Ospina-Tascón; Glenn Hernandez; Ingrid Alvarez; Luis E Calderón-Tapia; Ramiro Manzano-Nunez; Alvaro I Sánchez-Ortiz; Egardo Quiñones; Juan E Ruiz-Yucuma; José L Aldana; Jean-Louis Teboul; Alexandre Biasi Cavalcanti; Daniel De Backer; Jan Bakker
Journal:  Crit Care       Date:  2020-02-14       Impact factor: 9.097

9.  Does vasopressor therapy have an indication in hemorrhagic shock?

Authors:  François Beloncle; Ferhat Meziani; Nicolas Lerolle; Peter Radermacher; Pierre Asfar
Journal:  Ann Intensive Care       Date:  2013-05-22       Impact factor: 6.925

10.  Time to vasopressor initiation and organ failure progression in early septic shock.

Authors:  Lauren Page Black; Michael A Puskarich; Carmen Smotherman; Taylor Miller; Rosemarie Fernandez; Faheem W Guirgis
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-05-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.